Genmab — Oktober 2018
-
https://www.patientpower.info/video/a-look-ahead-expert-perspective-on-car-t-cell-therapy-vs-transplant-in-myeloma/
Dr. Krishnan:
"Exactly. We do know too is you first have to reduce the amount of myeloma in the body for CAR-T to work well and also to reduce the toxicity of CAR-T. So you can't just take someone with newly diagnosed myeloma and give them CAR-T cells" -
er der kommet forståelige data omkring duration på CAR-T? Det kunne lyde som om der er udfordringer?
-
ja, det er sgu ikke meget - hvis det så oven I købet ikke kan bruges i 1st line
-
Does that mean another treatment e.g. Dara, is necessary prior to using CAR-T?
-
Ok. Thank you E L. One thing is for sure, and that is that you know a hell of a lot more about it than I do

-
-
"
Ifølge den internationale investeringsbank J.P. Morgan kan Genmabs aktiekurs stige med op mod 18 procent, hvis studieresultaterne for alvor rammer skiven. Banken vurderer samtidig, at studiet vil blive offentliggjort inden for få uger".
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind